SECOND EXTENSION TO THE BOARD OF DIRECTORS CONSULTING AND CONFIDENTIALITY AGREEMENTBoard of Directors Consulting and Confidentiality Agreement • April 1st, 2002 • Paligent Inc • Biological products, (no disgnostic substances)
THIS SECOND EXTENSION TO THE BOARD OF DIRECTORS CONSULTING AND CONFIDENTIALITY AGREEMENT, AS AMENDED (the “ Second Extension”), is made as of this 9th day of February, 2001 (the “Effective Date”) by and between PALIGENT INC., a Delaware corporation (the “Company”) and Michael S. Weiss (the “Consultant”).
THIRD EXTENSION TO THE BOARD OF DIRECTORS CONSULTING AND CONFIDENTIALITY AGREEMENTBoard of Directors Consulting and Confidentiality Agreement • April 1st, 2002 • Paligent Inc • Biological products, (no disgnostic substances)
THIS THIRD EXTENSION TO THE BOARD OF DIRECTORS CONSULTING AND CONFIDENTIALITY AGREEMENT, AS AMENDED (the “Third Extension”), is made as of this 16th day of May, 2001 (the “Effective Date”) by and between PALIGENT INC., a Delaware corporation (the “Company”) and Elliott H. Vernon (the “Consultant”).
FOURTH EXTENSION TO THE BOARD OF DIRECTORS CONSULTING AND CONFIDENTIALITY AGREEMENTBoard of Directors Consulting and Confidentiality Agreement • April 1st, 2002 • Paligent Inc • Biological products, (no disgnostic substances)
THIS FOURTH EXTENSION TO THE BOARD OF DIRECTORS CONSULTING AND CONFIDENTIALITY AGREEMENT, AS AMENDED (the “Fourth Extension”), is made as of this 2nd day of January, 2002 (the “Effective Date”) by and between PALIGENT INC., a Delaware corporation (the “Company”) and Michael S. Weiss (the “Consultant”).
AMENDMENT #2 COOPERATIVE RESEARCH AND DEVELOPMENT AGREEMENT #303 CLINICAL DEVELOPMENT OF O6-BENZYLGUANINECooperative Research and Development Agreement • April 1st, 2002 • Paligent Inc • Biological products, (no disgnostic substances)
The purpose of this amendment is to change certain terms of the above referenced Cooperative Research and Development Agreement (CRADA). These changes are reflected below and, except for these changes and those of any previous amendments, all other provisions of the original CRADA remain in full force and effect. Three originals of this amendment are provided for execution; one is to remain with the National Cancer Institute; one with Procept, Inc. and one with AOI Pharmaceuticals, Inc.
PUBLIC HEALTH SERVICE PATENT LICENSE AGREEMENT—EXCLUSIVE COVER PAGEPatent License Agreement • April 1st, 2002 • Paligent Inc • Biological products, (no disgnostic substances) • New York
PHS, by executing interinstitutional agreements between the Milton S. Hershey Medical Center of Pennsylvania State University (L-067-02/0), and the University of Chicago (L-086-02/0), has obtained the exclusive license to, including the right to sublicense, the Licensed Patent Rights listed in Appendix A. Once executed, the terms and conditions of this Agreement shall supersede, and thereby terminate, the terms and conditions of the previous license agreement between the Licensee and the Pennsylvania State University, made effective on February 6, 1998
PALIGENT INC. FOURTH EXTENSION TO THE BOARD OF DIRECTORS CONSULTING AND CONFIDENTIALITY AGREEMENTBoard of Directors Consulting and Confidentiality Agreement • April 1st, 2002 • Paligent Inc • Biological products, (no disgnostic substances)
THIS FOURTH EXTENSION TO THE BOARD OF DIRECTORS CONSULTING AND CONFIDENTIALITY AGREEMENT, AS AMENDED (the “Fourth Extension”), is made as of this 2nd day of January, 2002 (the “Effective Date”) by and between PALIGENT INC., a Delaware corporation (the “Company”) and Zola P. Horovitz, Ph.D. (the “Consultant”).
THIRD EXTENSION TO THE BOARD OF DIRECTORS CONSULTING AND CONFIDENTIALITY AGREEMENTBoard of Directors Consulting and Confidentiality Agreement • April 1st, 2002 • Paligent Inc • Biological products, (no disgnostic substances)
THIS THIRD EXTENSION TO THE BOARD OF DIRECTORS CONSULTING AND CONFIDENTIALITY AGREEMENT, AS AMENDED (the “Third Extension”), is made as of this 16th day of May, 2001 (the “Effective Date”) by and between PALIGENT INC., a Delaware corporation (the “Company”) and Zola P. Horovitz, Ph.D. (the “Consultant”).
SECOND EXTENSION TO THE BOARD OF DIRECTORS CONSULTING AND CONFIDENTIALITY AGREEMENTBoard of Directors Consulting and Confidentiality Agreement • April 1st, 2002 • Paligent Inc • Biological products, (no disgnostic substances)
THIS SECOND EXTENSION TO THE BOARD OF DIRECTORS CONSULTING AND CONFIDENTIALITY AGREEMENT, AS AMENDED (the “ Second Extension”), is made as of this 9th day of February, 2001 (the “Effective Date”) by and between PALIGENT INC., a Delaware corporation (the “Company”) and Zola P. Horovitz, Ph.D. (the “Consultant”).
FOURTH EXTENSION TO THE BOARD OF DIRECTORS CONSULTING AND CONFIDENTIALITY AGREEMENTBoard of Directors Consulting and Confidentiality Agreement • April 1st, 2002 • Paligent Inc • Biological products, (no disgnostic substances)
THIS FOURTH EXTENSION TO THE BOARD OF DIRECTORS CONSULTING AND CONFIDENTIALITY AGREEMENT, AS AMENDED (the “Fourth Extension”), is made as of this 2nd day of January, 2002 (the “Effective Date”) by and between PALIGENT INC., a Delaware corporation (the “Company”) and Elliott H. Vernon (the “Consultant”).
THIRD EXTENSION TO THE BOARD OF DIRECTORS CONSULTING AND CONFIDENTIALITY AGREEMENTBoard of Directors Consulting and Confidentiality Agreement • April 1st, 2002 • Paligent Inc • Biological products, (no disgnostic substances)
THIS THIRD EXTENSION TO THE BOARD OF DIRECTORS CONSULTING AND CONFIDENTIALITY AGREEMENT, AS AMENDED (the “Third Extension”), is made as of this 16th day of May, 2001 (the “Effective Date”) by and between PALIGENT INC., a Delaware corporation (the “Company”) and Michael S. Weiss (the “Consultant”).
SECOND EXTENSION TO THE BOARD OF DIRECTORS CONSULTING AND CONFIDENTIALITY AGREEMENTBoard of Directors Consulting and Confidentiality Agreement • April 1st, 2002 • Paligent Inc • Biological products, (no disgnostic substances)
THIS SECOND EXTENSION TO THE BOARD OF DIRECTORS CONSULTING AND CONFIDENTIALITY AGREEMENT, AS AMENDED (the “ Second Extension”), is made as of this 9th day of February, 2001 (the “Effective Date”) by and between PALIGENT INC., a Delaware corporation (the “Company”) and Elliott H. Vernon (the “Consultant”).
